免疫疗法 | 靶点 | 厂家 | 适应症 | 状态 |
ipilimumab | anti-CTLA4单抗 | Medarex (BMS) | 黑素瘤 | approved |
tremelimumab | anti-CTLA4单抗 | Pfizer/ MedImmune (AstraZeneca) | 黑素瘤(失败)、非小细胞肺癌、间质瘤 | Phase I/II |
nivolumab | anti-PD1单抗 | Medarex (BMS) | 黑素瘤、非小细胞肺癌 | Phase III |
lambrolizumab | anti-PD1单抗 | Organon (Merck) | 黑素瘤、非小细胞肺癌 | Phase II |
pidilizumab | anti-PD1单抗 | CureTech | 淋巴瘤、白血病、实体瘤 | Phase II |
AMP-514 | anti-PD1单抗 | Amplimmune (AstraZeneca) | 实体瘤 | Phase I |
unkown | anti-PD1单抗 | 百济神州 | unkown | preclinical |
unkown | anti-PD1单抗? | CoStim Pharma (Novartis) | unkown | unkown |
AMP-224 | PDL2-Ig融合蛋白 | Amplimmune (AstraZeneca)/ GSK | 多种肿瘤 | Phase I |
AUNP-12 | PD1抑制剂(多肽) | Aurigene/ Pierre Fabre | unkown | preclinical |
MDX-1105 | anti-PDL1单抗 | Medarex (BMS) | 黑素瘤 | 失败? |
MPDL320A | anti-PDL1单抗 | Genentech | 黑素瘤 | Phase I |
MEDI4736 | anti-PDL1单抗 | MedImmune (AstraZeneca) | 实体瘤 | Phase I |
unkown | anti-PDL1单抗 | 百济神州 | unkown | 先导物优化 |
rHIgM12B7 | anti-PDL2单抗 | Mayo Clinic/NCI | 黑素瘤 | Phase I |
MGA271 | anti-B7H3单抗 | MacroGenics | 多种肿瘤 | Phase I |
AMP-110 | B7H4-Ig融合蛋白 | Amplimmune (AstraZeneca)/ Daiichi Sankyo | 类风湿性关节炎 | Phase I |
MEDI6469 | anti-OX40单抗 | MedImmune (AstraZeneca) | 实体瘤 | Phase I |
IMP321 | LAG3-Ig融合蛋白 | Immutep | 乳腺癌、肾癌 | Phase I |
CTL019 | CAR疗法 | Pennsylvania大学/ Novartis | ALL、NHL | Phase I |
UCART19 | CAR疗法 | Cellectis/Servier | unkown | unkown |
unkown | CAR疗法 | Juno Therapeutics | unkown | unkown |
IMCgp100 | TCR疗法 | Immunocore | 黑色瘤 | Phase I/II |
unkown | TCR疗法 | Immunocoer/ Genentech/ GSK/ AstraZeneca | unkown | unkown |
unkown | TCR疗法 | Juno Therapeutics | unkown | unkown |
欢迎光临 药群论坛 (http://www.yaoqun.net/) | Powered by Discuz! X3.2 |